Capital

MassMutual Ascend Adds the First Trust Barclays Edge Index to Its Suite of Fixed-Indexed Annuities

Retrieved on: 
Friday, March 22, 2024
Professional Services, Insurance, Finance, Senior, MassMutual, Pleasure, Capital, Barclays, First, Life insurance

MassMutual Ascend announced the addition of the First Trust Barclays Edge Index to its fixed-indexed annuities.

Key Points: 
  • MassMutual Ascend announced the addition of the First Trust Barclays Edge Index to its fixed-indexed annuities.
  • The First Trust Barclays Edge Index is a multi-asset index seeking to provide equity and fixed income exposure through a combination of indices, including Capital Strength™ Index and Value Line Dividend™ Index, while aiming to control risk by maintaining a volatility target at or below 7%.
  • The First Trust Barclays Edge Index now joins the diverse array of available strategies in the fixed-indexed and registered index-linked annuities offerings at MassMutual Ascend.
  • “We are very excited about working with First Trust® and Barclays,” said Joe Maringer, Senior Vice President and National Sales Manager.

Hercules Capital Receives Confirmed BBB Investment Grade Rating with Revised Outlook to Positive from Morningstar DBRS

Retrieved on: 
Thursday, March 21, 2024
Professional Services, Finance, Capital, Growth, DBRS, Ecosystem, BBB, Financial services

Hercules Capital, Inc. (NYSE: HTGC) (“Hercules” or the “Company”), the largest and leading specialty financing provider to innovative venture, growth and established stage companies backed by some of the leading and top-tier venture capital and select private equity firms, today announced that Morningstar DBRS (“DBRS”) has confirmed Hercules’ investment grade credit and corporate rating of BBB with a trend revision from Stable to Positive, as well as its underlying analysis.

Key Points: 
  • Hercules Capital, Inc. (NYSE: HTGC) (“Hercules” or the “Company”), the largest and leading specialty financing provider to innovative venture, growth and established stage companies backed by some of the leading and top-tier venture capital and select private equity firms, today announced that Morningstar DBRS (“DBRS”) has confirmed Hercules’ investment grade credit and corporate rating of BBB with a trend revision from Stable to Positive, as well as its underlying analysis.
  • “We are very pleased that DBRS has confirmed our BBB investment grade credit and corporate rating and revised the outlook to positive,” stated Seth Meyer, chief financial officer of Hercules.
  • Historical credit performance has been strong, underpinned by a well-designed risk management framework, and demonstrated solid underwriting and portfolio monitoring performance across multiple economic cycles.
  • The Company also has a broad, diversified funding profile and conservative regulatory leverage.

FedEx Reports Higher Third Quarter Diluted EPS of $3.51 and Adjusted Diluted EPS of $3.86

Retrieved on: 
Thursday, March 21, 2024
Logistics, Supply Chain Management, Air, Retail, Transport, Delivery Services, Failure, FedEx, Automation, Railway Labor Act, Annual report, Growth, MTM, Disease, EPS, DRIVE, Business, Name, ASR, EDT, Sale, Capital, Table, Security (finance), Insurance, Bank statement, United, FedEx Express, FedEx Ground, Investment, Atmosphere, Safety, GAAP, Geography, FDX, ETR, Share repurchase

FedEx Ground operating results increased due to lower structural costs resulting from DRIVE initiatives, higher base yield, and reduced self-insurance costs.

Key Points: 
  • FedEx Ground operating results increased due to lower structural costs resulting from DRIVE initiatives, higher base yield, and reduced self-insurance costs.
  • Cost per package was flat, as lower line-haul expense and improved dock productivity offset higher first- and last-mile costs.
  • The year-to-date decrease in outstanding shares benefited third quarter results by $0.09 per diluted share.
  • FedEx expects to repurchase an additional $500 million of common stock during the fiscal fourth quarter, which will bring the fiscal 2024 buyback total to $2.5 billion.

Mad Capital Launches $50 Million Perennial Fund II to Scale Regenerative Organic Agriculture in US

Retrieved on: 
Wednesday, March 20, 2024
Finance, Consulting, Agriculture, Natural Resources, Professional Services, Health, AG, Climate change, Farmer, Risk, Eric, Climate, Capital, PFI, Nature, Carbon, Senior, Biodiversity loss, Schmidt Family Foundation, Rockefeller Foundation, PFII, Multimedia, Investment, Soil, Organic

Mad Capital launched its Perennial Fund II (PFII) to provide farmers in the United States with tailored loans that help them transition to regenerative organic farmland while also increasing farmer profits.

Key Points: 
  • Mad Capital launched its Perennial Fund II (PFII) to provide farmers in the United States with tailored loans that help them transition to regenerative organic farmland while also increasing farmer profits.
  • "Mad Capital is playing an integral role in the transition to regenerative organic agriculture.
  • Launched in 2019, Mad Capital has been actively lending to regenerative organic farmers for five years.
  • The PFII brings Mad Capital closer to its ultimate goal of financing 5,000,000 acres of regenerative organic farmland by the end of 2032.

Monroe Capital Hires Waleed Noor as Head of Middle East and Plans to Open Abu Dhabi Office

Retrieved on: 
Wednesday, March 20, 2024
Professional Services, Other Professional Services, Finance, Construction & Property, Asset Management, REIT, Banque Saudi Fransi, Commerzbank, Risk management, Goldman Sachs, Crédit Agricole, Durham University, Capital, MEA, Nottingham University Business School

Monroe Capital LLC (“Monroe”) today announced it has expanded its platform to the Middle East with the appointment of Waleed Noor as Managing Director and Head of Middle East Distribution.

Key Points: 
  • Monroe Capital LLC (“Monroe”) today announced it has expanded its platform to the Middle East with the appointment of Waleed Noor as Managing Director and Head of Middle East Distribution.
  • Monroe is in the process of opening an office in Abu Dhabi.
  • Mr. Noor will be based in Abu Dhabi and be responsible for representing Monroe throughout the region.
  • We look forward to our continued strategic growth and expansion in the Middle East,” said Ted Koenig, Chairman and CEO of Monroe Capital.

Portal Biotechnologies Announces $5M Pre-Seed Round Led By Pear VC

Retrieved on: 
Tuesday, March 19, 2024
Other Manufacturing, Other Science, Technology, Research, General Health, Engineering, Manufacturing, Pharmaceutical, Other Professional Services, Medical Devices, Health Technology, Finance, Genetics, Nanotechnology, Professional Services, Artificial Intelligence, Biotechnology, Other Technology, Health, Hardware, Science, Innovation Center station, Gene editing, Cell, BRIC, RNA, Pear VC, Conscience, Capital, Messenger, Hope, Genome, Doctor of Philosophy, Bayer, Antibody, Kendall Square, CRISPR, Drug development, Multimedia, Small RNA, Silicon, Fine chemical

Today, Portal Biotechnologies, Inc. (“Portal”), a cell engineering platform company, announced a $5M pre-seed round led by Pear VC, with participation from Conscience VC and 10x Capital.

Key Points: 
  • Today, Portal Biotechnologies, Inc. (“Portal”), a cell engineering platform company, announced a $5M pre-seed round led by Pear VC, with participation from Conscience VC and 10x Capital.
  • Portal is committed to ensuring broad accessibility of its platform to enable a variety of research and therapeutic applications.
  • The company was founded by Armon Sharei, Ph.D., founder and former CEO of SQZ Biotechnologies.
  • “We are very excited to join the Portal team and support their mission to solve one of the field's major long-standing challenges,” said Eddie Eltoukhy, Partner and lead investor from Pear VC.

Coty Wins this year’s Euronext Best listing Award in the Large Cap category

Retrieved on: 
Tuesday, March 19, 2024
Finance, Luxury, Cosmetics, Retail, Professional Services, Capital, Conference, Growth, Euronext Growth, Best, Trust, Beauty, Skin, Euronext Paris, COTY, Security (finance)

Coty (NYSE: COTY) (Paris: COTY), one of the world’s largest beauty companies with a portfolio of iconic brands across fragrance, color cosmetics, skin and body care, has won this year’s Euronext Best Listing Award in the Large Cap category, at the 12th edition of the Euronext Annual Conference held on March 19, 2024 in Paris.

Key Points: 
  • Coty (NYSE: COTY) (Paris: COTY), one of the world’s largest beauty companies with a portfolio of iconic brands across fragrance, color cosmetics, skin and body care, has won this year’s Euronext Best Listing Award in the Large Cap category, at the 12th edition of the Euronext Annual Conference held on March 19, 2024 in Paris.
  • The award recognizes the success of Coty's global offering, the largest to date on Euronext Growth®.
  • The secondary listing on Euronext Paris was a resounding success for the company, raising €339.2 million, making it the 47th listing on Euronext in 2023 and the 11th international listing.
  • Sue Nabi, CEO of Coty, said: "We are immensely proud to receive this award for the Best Listing Award of the year in the Large Cap category, at the Euronext Stock Market Awards.

Meitheal Pharmaceuticals Announces Recent Business Progress Reinforcing Commitment to Sustainable Generics Development

Retrieved on: 
Tuesday, March 19, 2024
Health, Other Science, General Health, Research, Science, Pharmaceutical, Biotechnology, USP, Medication, NKF, ASHP, Fertility, Capital, Anesthetic, Society, Drug development, Nursing care plan, Bupivacaine, FDA, Food, Pharmaceutical industry

As we prepare to launch multiple new products in 2024, we are intently focused on expediting delivery of medicines in short supply,” said Tom Shea, Chief Executive Officer of Meitheal Pharmaceuticals.

Key Points: 
  • As we prepare to launch multiple new products in 2024, we are intently focused on expediting delivery of medicines in short supply,” said Tom Shea, Chief Executive Officer of Meitheal Pharmaceuticals.
  • As of March 1, 2024, both the U.S. Food and Drug Administration (FDA) and the American Society of Health-System Pharmacists (ASHP) websites list multiple presentations of Bupivacaine Hydrochloride Injection on drug shortage.
  • These approved lines add over 200 million units of capacity for vial and cartridge products that support current and future demand for generic injectables.
  • These lines are expected to produce commercial products that will have an impact on drug shortages beginning in the second half of 2024.

“Innovation Unleashed”: CAIA Association, in Conjunction with Some of the World’s Leading Asset Owners, Unveils The Rise of Total Portfolio Approach

Retrieved on: 
Tuesday, March 19, 2024
Finance, Consulting, Banking, Professional Services, Continuing, Training, Asset Management, Other Professional Services, Education, Organization, Conference, Future Fund, Chartered Alternative Investment Analyst, Risk, Capital, Unifi, Senior, WTW, CPP, TPA, Competition, GIC, Content, SAA, Culture, Investment, CAIA, Rise, Policy, Curriculum, Allocation

Joining Mr. Rubin in contributing to this seminal work are:

Key Points: 
  • Joining Mr. Rubin in contributing to this seminal work are:
    Rubin’s co-author and fellow CPP Investments senior leader Derek Walker, Managing Director, Head of Portfolio Design and Construction.
  • Charles Hyde, Head of Asset Allocation of New Zealand Superannuation Fund.
  • Swee Chiang Chiam, Head of Total Portfolio Policy and Allocation of GIC.
  • “As we point out in the report, TPA is not a monolithic methodology that can be applied off the shelf.

Engine Nominates Two Highly Qualified Candidates for Election to MRC Global’s Board of Directors at the 2024 Annual Meeting

Retrieved on: 
Tuesday, March 19, 2024
Other Manufacturing, Manufacturing, AOUT, Universal Health Services, Deluxe Corporation, Avid Technology, Executive, UBS, Fortress Investment Group, Mergers and acquisitions, American Outdoor Brands, Sale, Acquisition, MRC, Apax Partners, Capital, Bear, BSC, UHS, Security (finance)

Arnaud Ajdler, Engine’s Founder and Managing Member, commented:

Key Points: 
  • Arnaud Ajdler, Engine’s Founder and Managing Member, commented:
    “Engine has spent months engaging with MRC on its current strategy, capital allocation approach and Board composition.
  • Considering the size of our ownership position and our significant concerns, it is disappointing the Company has resisted working with us.
  • In our view, a Board that owns de minimis stock should not be willing to spend stockholder capital to keep an investor-designee from serving on a nine-member Board.
  • We look forward to engaging with our fellow shareholders on the case for adding stockholder-designees to MRC’s boardroom.